Maxcyte Share Discussion Threads

[adamb1978] 01/8/2023 18:00

Very funny Trident!

The next major turning point in MXCT is likely to be this summer/autumn, assuming the Crispr FDA approval comes through. Not only will it put that one on the path to pay royalties, but it'll raise the profile of MXCT's technology and pressurise/persuade other companies to accelerate their developments.

You do really need to take a long-term view with this one though. Really just own and let it run

[trident5] 01/8/2023 16:22

To answer Jones 1961 then - 5 to 10 years.

[adamb1978] 01/8/2023 15:26

Thats a difference between UK and US stock amrkets Trident, and will have been what drove them to move to the US. In US markets, its ok for companies to burn cash in order to grow. On the LSE, its difficult for companies to do that

MXCT have enough cash to last 5-10 years, by which time they'll be profitable

[trident5] 01/8/2023 14:49

When it turns a profit/positive cash flow?

[jones1961] 01/8/2023 14:34

The current share price makes no sense whatsoever. On 6th July it announced license deal with Lyell Immunopharma, shares closed at $4.39, on 10th July it announced license deal with Vittoria Biotherapeutics, shares closed at Vittoria Biotherapeutics $4.99. Today it announces license deal with Prime Medicine, shares currntly trading at $4.495. There have been 3 new deals in the space of 1 month. Maxcyte now has 23 strategic partnerships, each of which generates pre-commercial milestone revenue and the vast majority of which include sales-based payments. When will people wake up to this stock?

[adamb1978] 01/8/2023 12:29

....and another!

[adamb1978] 10/7/2023 12:10

Like London busses....another SPL!

[adamb1978] 09/7/2023 11:20

Pfizer investment in Caribou is a nice vote of confidence in what they're developing

[edwardt] 06/7/2023 18:48

We linked to caribou?

[epicwarlock] 13/6/2023 10:35

Encouraging share price movement and the short term technicals look decent too.All that said, I'm in this for the long term in my SIPP (my largest stake actually since taking some profits on 888)Could multibag on positive R&D developments later this year, or perhaps next, while the downside of current revenue sources protects to the downside. So overall I'm comfy with the risk/reward profile

[adamb1978] 03/6/2023 09:13

Thanks Davep4. I'm not sure exactly how the 6 months 'take action' bit in your 1362 post (which I wasnt aware of) compares with the 8 months, which you also refer to in the 1360 post...though either way, both suggest a decision in H2 at some point. I'm also not sure how the rolling filing route which they went down impacts things and whether it speeds it up. Again, it the bigger scheme of things its somewhat irrelevant though

[davep4] 02/6/2023 23:56

From FDA website

Priority Review means that FDA aims to take action on an application within six months, compared to 10 months under standard review. A Priority Review designation directs attention and resources to evaluate drugs that would significantly improve the treatment, diagnosis, or prevention of serious conditions. More information about Priority Review is here.

[davep4] 02/6/2023 23:30

From a Press Release dated 4 April 2023

Vertex Pharmaceuticals and CRISPR Therapeutics have completed the rolling submission of biologics licence applications (BLAs) to the US Food and Drug Administration (FDA) for exagamglogene autotemcel (exa-cel) to treat sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT).

The applications include requests for priority review. If granted, these would shorten the time taken for application review to eight months.

[adamb1978] 01/6/2023 15:55

Main news event this year will be FDA approval of exa-cel. Last possible date for that is November I believe. No idea whether these things typically go the distance. Most other things this year will pale into into insignificance I believe

[epicwarlock] 01/6/2023 14:51

Um, yes please (cheesy grin!)I guess I'm just trying to remind myself of when when the next update is (3 more months?) and whether anyone is aware of anything brewing that might lead to an ad hoc updateGuess I'm just frustrated at seeing this holding onto it's last dip following the recent (miserable) trading update....

[trident5] 01/6/2023 14:47

You want the news before it comes out?

[epicwarlock] 01/6/2023 14:36

Where's the love for MXCT? Anyone clued in on any newsflow which may get this moving one way or another?

[adamb1978] 11/5/2023 08:08

Hi 2theduke

Yes, its the way US companies report unfortunately. Very factual and limited commentary. Really need to listen to the Q&A part of earnings calls in order to get the colour

Agree that the cash balance puts a floor under things. All small companies encounter bumps in the road. Thankfully this is bump in the road for MXCT won't be terminal - just annoying

There's a couple new slides in their investor presentation on their website which gives comfort about the pipeline of treatments which its customers are developing

Adam

[2theduke] 11/5/2023 07:49

Many thanks for the insight Adam.
The commentary, and some from the LSE Board is good insight. It clearly should form part of the update, it's never good when educated Pi's start filling in the gaps.
I'd like to know more about Asian partners and incomes, LG would be an interesting case study.
I wonder how their new NPV slide will look with a new cfo now.
Given the cash of 240m, the share is protected so there's no panic here and makes the long run one we can wait for easily enough whilst they sort themselves out

[adamb1978] 11/5/2023 07:36

2theduke

In terms of drivers, they said on the call last night that consumables were pulled forward in H1 2022 as a result of the world emerging from covid and customers buying more in the lead up to approvals (ie CRISPR). That made 2022 different to their normal 40/60 H1/H2 split for the core business, and hasnt been helped by the funding environment for their customers either.

All that sounds plausible. Based on the CRISPR approval timing, I'd imagine we'll see a strong Q3 or Q4 around the time when approval comes in, and which probably helps justify their 40/60 split for 2023.

DD said that they have close relationships with their customers so have good visibility on likely demand

The 2022 pull forward is annoying. It pushes out the revenue line say 6 months or so but with this being a very long-term investment, I dont think it fundamentally changes the story and I guess all investments dont go from bottom left to top right in a straight line

Adam

[2theduke] 11/5/2023 07:30

I'd add - it's time for management to stop selling stock now. They barely hold any as it is and it's not a good look.